NIT2

Across TCGA pan-cancer cohorts, NIT2 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of NIT2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where NIT2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NIT2 is over-expressed in tumor, although a few such as KICH and LIHC show the opposite, repressed pattern.

BLCA, COAD, and KIRC are the cancer types where NIT2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NIT2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Female	III,IV	+1.118	<.001	12	view →
COAD	Female	II,III,IV	+0.943	<.001	10	view →
KIRC	All	III,IV	+0.511	<.001	10	view →
LUAD	Female	All	+0.526	<.001	9	view →
KICH	Female	II,III,IV	−2.062	<.001	8	view →
HNSC	Male	III,IV	+0.891	<.001	8	view →
STAD	All	II,III,IV	+0.666	<.001	8	view →
READ	Female	All	+0.950	<.001	7	view →
LUSC	Female	All	+1.096	<.001	6	view →
BRCA	All	III,IV	+0.479	<.001	6	view →
ESCA	All	II,III,IV	+0.900	.001	4	view →
PRAD	All	All	+0.320	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

NIT2–BLCA

Open the BLCA breakdown →